0001062993-23-013932.txt : 20230621
0001062993-23-013932.hdr.sgml : 20230621
20230621184606
ACCESSION NUMBER: 0001062993-23-013932
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20230620
FILED AS OF DATE: 20230621
DATE AS OF CHANGE: 20230621
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McWherter Charles
CENTRAL INDEX KEY: 0001588862
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36500
FILM NUMBER: 231031125
MAIL ADDRESS:
STREET 1: C/O CYMABAY THERAPEUTICS, INC.
STREET 2: 7575 GATEWAY BLVD., SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CymaBay Therapeutics, Inc.
CENTRAL INDEX KEY: 0001042074
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943103561
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7575 GATEWAY BOULEVARD
STREET 2: SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
BUSINESS PHONE: 510-293-8800
MAIL ADDRESS:
STREET 1: 7575 GATEWAY BOULEVARD
STREET 2: SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
FORMER COMPANY:
FORMER CONFORMED NAME: METABOLEX, INC.
DATE OF NAME CHANGE: 20090721
FORMER COMPANY:
FORMER CONFORMED NAME: METABOLEX INC
DATE OF NAME CHANGE: 19970710
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0407
4
2023-06-20
0001042074
CymaBay Therapeutics, Inc.
CBAY
0001588862
McWherter Charles
C/O CYMABAY THERAPEUTICS, INC.
7575 GATEWAY BLVD., SUITE 110
NEWARK
CA
94560
0
1
0
0
President of R&D
0
Common Stock
2023-06-20
4
M
0
21749
5.00
A
36749
D
Common Stock
2023-06-20
4
S
0
21749
8.1559
D
15000
D
Employee Stock Option (right to buy)
5.00
2023-06-20
4
M
0
10407
0
D
2023-10-30
Common Stock
10407
41616
D
Employee Stock Option (right to buy)
5.00
2023-06-20
4
M
0
708
0
D
2023-12-22
Common Stock
708
4244
D
Employee Stock Option (right to buy)
5.00
2023-06-20
4
M
0
236
0
D
2023-12-22
Common Stock
236
1414
D
Employee Stock Option (right to buy)
5.00
2023-06-20
4
M
0
3892
0
D
2023-12-22
Common Stock
3892
23350
D
Employee Stock Option (right to buy)
5.00
2023-06-20
4
M
0
6506
0
D
2024-01-05
Common Stock
6506
39034
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 24, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.1 to $8.245, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option vested as to 1/3 of the underlying shares on October 31, 2013 and the remaining 2/3 of the underlying shares vested ratably on a monthly basis over the 48 months thereafter.
The original option vested as to 1/4 of the underlying shares on July 23, 2008 and the remaining 3/4 of the underlying shares vested ratably on a monthly basis over the 36 months thereafter.
The original option vested as to 1/48 of the underlying shares monthly from October 15, 2009.
The option vested in full on December 23, 2015.
The option vested as to 1/3 of the underlying shares on January 6, 2014 and the remaining 2/3 of the underlying shares vested ratably on a monthly basis over the 48 months thereafter.
/s/ Paul Quinlan, as attorney-in-fact for Charles McWherter
2023-06-20
EX-24
2
exhibit24.txt
POWER OF ATTORNEY
POWER OF ATTORNEY
Know all by these presents, that the undersigned
hereby constitutes and appoints each of SUJAL SHAH,
DANIEL MENOLD, PAUL T. QUINLAN, DIANA KWON,
MATTHEW HEMINGTON and BRETT WHITE,
signing individually, the undersigned's true and
lawful attorneys-in-fact and agents to:
(1) execute for and on behalf of the undersigned,
an officer, director or holder of 10% of more of
a registered class of securities of CymaBay
Therapeutics, Inc. (the Company), Forms 3, 4
and 5 in accordance with Section 16(a) of the
Securities Exchange Act of 1934, as amended (the
Exchange Act) and the rules thereunder;
(2) do and perform any and all acts for and on
behalf of the undersigned that may be necessary
or desirable to complete and execute such Form 3,
4 or 5, complete and execute any amendment or
amendments thereto, and timely file such forms or
amendments with the United States Securities and
Exchange Commission and any stock exchange or
similar authority; and
(3) take any other action of any nature
whatsoever in connection with the foregoing which,
in the opinion of such attorney-in-fact, may be of
benefit, in the best interest of, or legally
required by, the undersigned, it being understood
that the documents executed by such attorney-in-fact
on behalf of the undersigned pursuant to this Power
of Attorney shall be in such form and shall contain
such terms and conditions as such attorney-in-fact
may approve in such attorney-in-fact's discretion.
The undersigned hereby grants to each such
attorney-in-fact full power and authority to do and
perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the
exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as
the undersigned might or could do if personally
present, with full power of substitution or
revocation, hereby ratifying and confirming all
that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes,
shall lawfully do or cause to be done by virtue
of this power of attorney and the rights and
powers herein granted. The undersigned acknowledges
that the foregoing attorneys-in-fact, in serving in
such capacity at the request of the undersigned,
responsibilities to comply with Section 16 of the
Exchange Act.
This Power of Attorney shall remain in full force
and effect until the earliest to occur of (a) the
undersigned is no longer required to file Forms 3,
4 and 5 with respect to the undersigned's holdings
of and transactions in securities issued by the
Company, (b) revocation by the undersigned in a
signed writing delivered to the foregoing
attorneys-in-fact, or (c) as to any attorney-in-fact
individually, until such attorney-in-fact shall no
longer be employed by the Company or Cooley LLP, as
the case may be.
/s/ Charles McWherter
Charles McWherter